1. Home
  2. LGVN vs SNAL Comparison

LGVN vs SNAL Comparison

Compare LGVN & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.76

Market Cap

25.9M

Sector

Health Care

ML Signal

HOLD

Logo Snail Inc.

SNAL

Snail Inc.

HOLD

Current Price

$4.14

Market Cap

26.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGVN
SNAL
Founded
2014
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
25.9M
26.6M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
LGVN
SNAL
Price
$0.76
$4.14
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
215.0K
437.8K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
50.76
120.00
EPS
N/A
N/A
Revenue
$709,000.00
$81,225,622.00
Revenue This Year
N/A
$15.53
Revenue Next Year
$10.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.34
52 Week High
$1.27
$5.92

Technical Indicators

Market Signals
Indicator
LGVN
SNAL
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
LGVN
SNAL

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

About SNAL Snail Inc.

Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.

Share on Social Networks: